Welcome to our dedicated page for CS Diagnostics news (Ticker: CSDX), a resource for investors and traders seeking the latest updates and insights on CS Diagnostics stock.
CS Diagnostics Corp. (OTCQB: CSDX) is a Wyoming-incorporated medical technology and biotechnology company that regularly issues news on its advanced diagnostic and protective solutions. As part of CS Group, the company reports on developments related to its flagship products CS-Protect Hydrogel and MEDUSA, as well as regulatory progress, financing initiatives, and group-level collaborations in healthcare and hygiene.
News updates often cover product milestones, including FDA and EPA regulatory steps for CS-Protect Hydrogel and MEDUSA, patent application activity, and international authorizations. The company also releases information about manufacturing partnerships, such as arrangements for MEDUSA production, and about demand trends in sectors like hospitals, hotels, and schools where its surface disinfectant products are used.
Investors and observers can find capital markets and corporate governance news, including announcements of Regulation D, Rule 506(c) offerings, proposed financing agreements involving preferred stock, and steps toward enhanced SEC reporting status. CS Diagnostics Corp. also reports on corporate actions such as the conversion of preferred shares into common stock to support consolidated financial reporting across its affiliates.
Additional news items include participation in investor conferences, group-level valuations of key product lines, and statements from company leadership on strategic direction, regulatory alignment, and global expansion plans. This news feed provides a centralized view of how CS Diagnostics Corp. is advancing CS-Protect Hydrogel, MEDUSA, and related healthcare technologies across multiple regions and regulatory frameworks.
CS Group (OTCQB: CSDX) outlined a multi-channel sales model, global logistics partners, and a sustainability roadmap to support commercial rollout of MEDUSA SDP on Jan 21, 2026. Distribution will target institutional B2B channels—hospitals, gyms, schools, corporate clients—and B2C routes including physical retail in UAE and Germany, major online marketplaces, and direct-to-consumer e-commerce. DHL is appointed for bulk/institutional shipments and FedEx for retail and consumer deliveries. The company plans to begin regulatory approval processes for a bio-degradable, dissolving MEDUSA SDP wet wipes line as part of its sustainability roadmap, positioning the product for global fulfillment and future market expansion.
CS Diagnostics Corp (OTCQB:CSDX) announced that affiliates CS Interpharm and CS Diagnostics Pharma have completed conversion of their Series B preferred shares into unrestricted common stock. The conversion supports the company's plan to prepare consolidated financial statements by fiscal year-end, December 31, 2025, and to simplify equity structure by eliminating preferred dividend tracking.
Management says the move will increase transparency, streamline administration, improve alignment among affiliates, and strengthen CSDX's position for capital-market access and potential uplisting.
CS Diagnostics Corp. (OTCQB:CSDX) launched a Regulation D, Rule 506(c) offering on October 13, 2025, selling CSDX Preferred C Shares to U.S. accredited and non-U.S. investors to fund commercialization of CS Protect Hydrogel and MEDUSA.
Net proceeds are planned to be allocated roughly: Regulatory 20–25%, Manufacturing 15–20%, Sales & Marketing 20–25%, R&D 10–15%, Working capital 10–15%, and Token/platform support 5–10%. Offering documents (PPM, Subscription Agreement) are available on the company website.
CS Diagnostics Corp. (OTCQB: CSDX) announced significant progress across multiple fronts, including regulatory advancements for its flagship products and strong financial growth. The company's CS-Protect Hydrogel is under FDA review and has initiated patent filings in multiple countries. Their protective solution MEDUSA has secured authorization in the UAE and Europe, with EPA review ongoing in the US.
CSI, their subsidiary, reported a 75% increase in turnover for 2025 compared to 2024's $3.5 million. CSDX is launching a Regulation D offering and plans to become fully SEC-reporting by end of September 2025. The company is preparing for European market entry with MEDUSA shipments scheduled for October 2025.
CS Diagnostics Corp. (OTCQB:CSDX) has submitted a patent application for its CS-Protect Hydrogel technology, marking a significant milestone in its FDA application process. The company has partnered with Paul & Albrecht Patentanwälte, a prestigious German intellectual property law firm, to protect its innovative organ spacer medical device.
CS-Protect Hydrogel stands out for its versatility in treating various pathologies, featuring advanced molecular structure and chemical physical properties. The partnership with Paul & Albrecht, established in 1977, aims to ensure robust international intellectual property protection for CS Diagnostics' innovations.
CS Diagnostics Corp. (OTCQB:CSDX) has submitted its final Form F-10 registration statement draft to the Processing Team for Edgardization and subsequent filing with the SEC. This regulatory filing represents a strategic move towards enhancing market presence and transparency.
Company executives highlighted the significance of this filing, with Board President Thomas Fahrhoefer emphasizing its alignment with market regulatory standards, while Vice President Mohammad EsSayed noted it as a foundational step in the company's journey toward a potential Nasdaq listing.
CS Group (CSDX) has announced that its subsidiary CS Interpharm General Trading CO. LLC has signed a Memorandum of Understanding (MOU) and Non-Disclosure Agreement (NDA) with Gulf Center Group, a UAE-based manufacturer of plastic packaging and hygiene-related chemicals.
Under the agreement, Gulf Center Group will provide exclusive end-to-end manufacturing support for CS Group's MEDUSA product line, including customized bottle design, filling, and production services. The collaboration aims to align with MEDUSA brand's identity and quality standards.
According to company executives, this partnership represents a strategic move to enhance the product line and secure reliable manufacturing support while strengthening supply chain capabilities in the UAE region.
CS Group has completed a valuation of its MEDUSA surface disinfectant, estimating its fair market value at USD 513 Million as of April 1, 2025. The company is in discussions with healthcare providers, facilities management companies, and distribution partners across multiple regions to accelerate global market entry.
The surface disinfectant market is projected to grow from USD 5.46 Billion in 2023 to USD 8.84 Billion by 2030. CS Group estimates MEDUSA can capture up to 3% market share by 2030 through B2B and retail channel expansion. The product's key advantage lies in its reduced application frequency in high-traffic environments, offering cost and labor savings compared to competitors requiring frequent reapplication.
CS Diagnostics Corp. (OTCQB:CSDX) has received a Letter of Intent from SAN ART CAPITAL SAS for a proposed $5 million equity loan in exchange for Series C Preferred Stock. The funding agreement aims to support the production and commercialization of CS Diagnostic's assets, particularly the CS-Protect Hydrogel and MEDUSA products in global markets.
The funds will be allocated to support the commercial rollout of CS-Protect Hydrogel, further R&D, operational expansions, and obtaining U.S. EPA approval for the Smart Disinfectant Product MEDUSA. The parties are proceeding with final due diligence and definitive agreement negotiations, targeting closure in the coming weeks.
FAQ
What is the current stock price of CS Diagnostics (CSDX)?
What is the market cap of CS Diagnostics (CSDX)?
